Collegium Pharmaceutical (COLL) reported $781M in revenue for fiscal 2025, +23.6% year on year. That ranks #1934 by revenue among 2853 SEC filers and #182 in Healthcare. Net income was $63.0M, a net margin of 8.1%. Revenue has grown 97.5% a year on average since 2016 ($1.7M then). The fiscal 2025 balance sheet shows $1.7B in total assets, $231M in cash and $11.5M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $781M | +23.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $463M | +22.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $180M | +5.7% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $63.0M | −8.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $329M | +60.7% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.7M | +5.3% | FY20252025-12-31 |
| Total assetsAssets | $1.7B | −0.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $302M | +31.8% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $231M | +227.7% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $11.5M | 0.0% | FY20192019-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $194M | $14.5M | Open → |
| Q2 20262026-06-30 | $200M | −$15.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Collegium Pharmaceutical, Inc
- Ticker
- COLL
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001267565
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Caris Life SciencesCAI | $812M | −$68.1M |
| Telix PharmaceuticalsTLX | $804M | −$7.1M |
| U S Physical TherapyUSPH | $781M | $39.6M |
| Collegium PharmaceuticalCOLL | $781M | $63.0M |
| Alphatec HoldingsATEC | $764M | −$143M |
| Corcept TherapeuticsCORT | $761M | $99.7M |
| Irhythm HoldingsIRTC | $747M | −$45.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Collegium Pharmaceutical — Key figures |url=https://companiesranked.com/en/company/collegium-pharmaceutical |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Collegium Pharmaceutical — Key figures. CompaniesRanked. https://companiesranked.com/en/company/collegium-pharmaceuticalBibTeX
@misc{companiesranked-en-company-collegium-pharmaceutical-2026,
author = {{CompaniesRanked}},
title = {{Collegium Pharmaceutical — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/collegium-pharmaceutical}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-011992 · February 26, 2026
{{cite web |title=Collegium Pharmaceutical — Key figures — 10-K (0001628280-26-011992) |url=https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/coll-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.